Jonathan Jacinto
Overview
Explore the profile of Jonathan Jacinto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moore G, Zeng V, Diaz J, Bonzon C, Avery K, Rashid R, et al.
Mol Cancer Ther
. 2024 Sep;
24(3):331-344.
PMID: 39301613
T-cell activation is a multistep process requiring T-cell receptor engagement by peptide-MHC complexes (Signal 1) coupled with CD28-mediated costimulation (Signal 2). Tumors typically lack expression of CD28 ligands, so tumor-specific...
2.
Moore G, Bernett M, Rashid R, Pong E, Nguyen D, Jacinto J, et al.
Methods
. 2018 Oct;
154:38-50.
PMID: 30366098
Bispecific monoclonal antibodies can bind two protein targets simultaneously and enable therapeutic modalities inaccessible by traditional mAbs. Bispecific formats containing a heterodimeric Fc region are of particular interest, as a...
3.
Moore G, Bautista C, Pong E, Nguyen D, Jacinto J, Eivazi A, et al.
MAbs
. 2011 Nov;
3(6):546-57.
PMID: 22123055
Bispecific antibodies based on full-length antibody structures are more optimal than fragment-based formats because they benefit from the favorable properties of the Fc region. However, the homodimeric nature of Fc...
4.
Bernett M, Karki S, Moore G, Leung I, Chen H, Pong E, et al.
J Mol Biol
. 2010 Jan;
396(5):1474-90.
PMID: 20045416
Fully human monoclonal antibodies (mAbs) derived from transgenic mice or human antibody libraries are the current state of the art for reducing the immunogenicity risk of antibody drugs. Here, we...
5.
Lazar G, Desjarlais J, Jacinto J, Karki S, Hammond P
Mol Immunol
. 2006 Nov;
44(8):1986-98.
PMID: 17079018
We introduce a new method of humanization based on a novel and immunologically relevant metric of antibody humanness, termed human string content (HSC), that quantifies a sequence at the level...
6.
Barbosa M, Vielmetter J, Chu S, Smith D, Jacinto J
Clin Immunol
. 2005 Nov;
118(1):42-50.
PMID: 16260183
Interferon-beta (IFN-beta) is currently the first-line therapy for the treatment of multiple sclerosis (MS). However, a significant percentage of MS patients develop anti-IFN-beta antibodies, which can reduce the efficacy of...